Skip to main content

Advertisement

Table 5 Clinicopathological factors in relation to disease-free and breast cancer-specific survival

From: Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer

  Disease-free survival Breast cancer-specific survival
  Numbera Events P valueb Numbera Events P valueb
Variables       
Clinicopathological factors       
   Age at diagnosis       
≤ 59 years 83 28 0.163 83 19 0.005c
> 59 years 63 25   67 29  
   Tumour sized       
pT1 47 11 0.007c 48 9 0.013c
pT2 to pT4 97 42   100 39  
   Lymph node statusd       
pN0 67 9 < 0.001c 67 10 < 0.001c
pN1 to pN3 76 41   80 35  
   Histological grade       
G1 and G2 81 23 0.008c 83 19 0.002c
G3 64 30   66 29  
   Histological type       
Ductal 120 46 0.376 122 40 0.474
Lobular 11 4   12 5  
Other 15 3   16 3  
   Tumour focality       
Unifocal 127 44 0.158 130 39 0.082
Multifocal 18 9   19 9  
   Oestrogen receptor       
Negative (IRSe ≤ 2) 38 16 0.351 38 16 0.101
Positive (IRS > 2) 79 25   83 22  
   Progesterone receptor       
Negative (IRSe ≤ 2) 81 32 0.214 85 32 0.056
Positive (IRS > 2) 40 11   40 8  
   Her2 status       
Negative (IHC: 0; 1+) 101 38 0.840 105 33 0.445
Positive (IHC: 2+; 3+) 23 9   23 9  
   EDN3 expression       
Low (IRSe < 8) 67 28 0.167 68 28 0.022c
High (IRS ≥ 8) 79 25   82 20  
  1. aOnly female patients with primary invasive breast cancer were included. bLog-rank test. cSignificant data. dAccording to the UICC (Union Internationale contre le Cancer): TNM Classification of Malignant Tumours [19].eImmunoreactivity score (IRS) according to Remmele and Stegner [24]. EDN3, endothelin-3; IHC, immunohistochemistry.